Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camizestrant Plus Ribociclib in HR+ Breast Cancer
NCT07195227Phase 2Recruiting
- Sponsor
- MEDSIR
- Start
- Mar 2026
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of camizestrant in breast cancer, sponsored by MEDSIR. Started Mar 2026; status: recruiting.
02
Drugs
camizestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07195227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07195227.